To compare dosing profi les between duloxetine and pregabalin among patients with fi bromyalgia. METHODS: A retrospective cohort study was conducted on a large U.S. administrative claims database to examine commercially insured individuals aged 18 to 64 who had fi bromyalgia and initiated (a 90-day clean period before initiation) duloxetine or pregabalin in 2007. Continuous enrollment in the 12 months pre-and post-index periods and at least 30-day supply of duloxetine or pregabalin over the 1-year follow-up were required for all selected patients. Average daily doses of all duloxetine or pregabalin prescriptions per person, average daily dose and average daily costs in each of the fi rst 12 prescriptions, percent of patients with increased or decreased dose, and percent of daily dose change from previous prescription were compared between duloxetine and pregabalin cohorts. RESULTS: Both the duloxetine (n = 1699) and pregabalin (n = 2560) cohorts had a mean age of 51~52 years. Duloxetine-treated patients had an average initial daily dose of 55.6 mg versus 159.8 mg for the pregabalin-treated patients. The average daily dose per patient was 55.7 mg for duloxetine and 195.4 mg for pregabalin. The average duloxetine daily doses and daily costs ranged from 55.0 mg-60.2 mg and $3.9-$5.0 for the fi rst 12 prescriptions and 159.8 mg-265.7 mg and $4.4-$5.0 for pregabalin. The percentages of daily-dose changes from previous prescription were −5.4%~3.0% for duloxetine and −1.0%~16.6% for pregabalin. Over the 1-year follow-up, both the percentages of patients with a dose increase (17.3% for duloxetine vs. 51.8% for pregabalin, P < 0.01) and a dose decrease (24.8% for duloxetine vs. 10.0% for pregabalin P < 0.01) were statistically different between cohorts. CONCLUSIONS: Among patients with fi bromyalgia, duloxetine and pregabalin initiators had very different dosing profi les. The average daily dose for duloxetine was relatively stable over time, while pregabalintreated patients had signifi cant dose escalation over the 12-month follow-up period. To compare dosing patterns between patients with fi bromyalgia who had high versus low duloxetine or pregabalin compliance, respectively. METHODS: Using a large U.S. administrative claims database, commercially insured patients aged 18-64 who had fi bromyalgia and initiated duloxetine or pregabalin in 2007 were examined. Medication compliance was measured via medication possession ratio (MPR), with MPR¡Ý (<) 0.8 as high (low) compliance. All patients selected had continuous enrollment in the 12-month pre-and post-index periods, at least 30 days¡ − supply of duloxetine or pregabalin in the 12-month post-index period, and were classifi ed into 4 mutually exclusive cohorts based on their initiation agents (duloxetine vs. pregabalin) and compliance levels (high vs. low). Average daily doses of the fi rst 8 prescriptions and duration between the initial dose and the fi rst increased dose were compared across cohorts. RESULTS: Compared to the low compliance patients, patients with high compliance had signifi cantly higher initial (duloxetine [N = 804 vs. 895]: 56.0 mg vs. 55.2 mg; pregablin [N = 710 vs. 1,850]: 164.9 mg vs. 157.9 mg) and average (duloxetine: 57.0 mg vs. 54.6 mg; pregabalin: 216.8 mg vs. 187.1 mg) daily doses (all P < .05). The average daily doses for the fi rst 8 prescriptions ranged from 55.0 mg-58.3 mg and 56.0 mg-60.6 mg for duloxetine high and low compliance patients, respectively, while the pregabalin-treated patients had 157.9 mg-238.8 mg and 164.9 mg-248.3 mg, correspondingly. The duration from the initial dose to the fi rst dose increase was 263.5 vs. 161.1 days (P < .05) for the duloxetine high versus low compliance patients and 268 vs. 135.4 days for the pregabalin high versus low compliance patients, respectively. CONCLUSIONS: Among patients with fi bromyalgia, duloxetine and pregabalin initiators had different dosing patterns by compliance levels. Both duloxetine-and pregabalin-treated patients with high compliance had higher initial and average daily doses than those with low compliance. The average daily dose remained stable over time for duloxetine, however, increased for pregabalin for both compliance groups.
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PMS48 PSYCHOMETRIC PROPERTIES OF THE GREEK MODIFIED HEALTH ASSESSMENT QUESTIONNAIRE FOR ASSESSING PHYSICAL DISABILITY IN RHEUMATOID ARTHRITIS
Kontodimopoulos N 1 , Bozios P 2 , Raftakis I 2 , Elmatzoglou I 2 , Yfantopoulos J 3 , Niakas D 1 1 Hellenic Open University, Patras, Greece; 2 Asklipieio Voulas General Hospital, Voula, Greece; 3 National and Kapodistrian University of Athens, Athens, Greece OBJECTIVES: To test basic psychometric properties (validity, reliability and responsiveness) of the Greek version of the Modifi ed Stanford Health Assessment Questionnaire (MHAQ) for assessment of physical disability in rheumatoid arthritis (RA).
METHODS:
The sample consisted of 120 RA patients (60.0% female, mean age 59.0) starting on biological antirheumatic drugs. Outcome measures were the MHAQ, the Disease Activity Score (DAS28) and the EQ-5D completed at baseline and at 3 months post-intervention. Item response frequencies and ceiling/fl oor effects were examined. Internal consistency reliability was assessed with Cronbach's alpha. Construct validity was examined by correlating baseline item and total scores of the MHAQ, with the EQ-5D and DAS28. MHAQ items were also tested for their correlation with the principal component. Effect sizes between MHAQ baseline and three-month data were compared to respective values for the other outcomes for evidence of responsiveness. RESULTS: Floor and ceiling effects for the eight MHAQ items ranged between 0-21.7% and 0.8-4.2% respectively, and the full range of responses was used in all but one item. Cronbach's alpha was 0.89 at baseline and 0.86 at three months post intervention, indicating good internal consistency of the instrument. Moderate correlations were noted (Spearman's ρ of 0.3 to 0.5) between most MHAQ and EQ-5D domains, and between the overall scores, and strong correlations (ρ > 0.5) between MHAQ and DAS28. Principal component analysis resulted in one factor explaining 57.1% of the total variance of the scale and all 8 items had high correlation coeffi cients (range 0.561-0.862) with this principal component. Responsiveness was satisfactory as the MHAQ effect size was 0.41, comparable to EQ-5D and DAS28 effect sizes (0.46 and 0.33 respectively). CONCLUSIONS: Evidence has been provided to support the reliability, validity and sensitivity to change of the Greek version of the MHAQ in the evaluation of functional status of RA patients.
PMS49 PSYCHOMETRIC PROPERTIES OF THE RHEUMATOID ARTHRITIS DISEASE ACTIVITY INDEX (RADAI) IN A COMMUNITY POPULATION IN THE US
Bharmal M 1 , Cascade E 2 1 Quintiles, Rockville, MD, USA; 2 iGuard, Inc, Rockville, MD, USA OBJECTIVES: The Rheumatoid Arthritis Disease Activity Index (RADAI) was developed to provide an easy to use self-administered assessment of rheumatoid arthritis (RA) to complement physician assessment. This study evaluates the psychometric properties of a web administered version of the RADAI in a community sample in the US. METHODS: A random sample of iGuard.org members in the US treated with medications for RA completed the RADAI and a series of other questions related to their disease. iGuard.org is a free medication monitoring service that is introduced to patients through multiple sources including physician, pharmacy and online referrals. Internal consistency of the RADAI was evaluated using Cronbach's alpha and itemtotal correlations, and factor analysis was used to confi rm the domain structure. Convergent validity was established using correlations with patient global assessment of pain and number of painful joints. RESULTS: A total of 153 RA patients completed the study. The mean (SD) age of respondents was 52.7 (10.9) years, 71.2% were females with 54.3% diagnosed with RA 1 to 5 years ago and 39.2% diagnosed 5 to 15 years ago. The mean (SD) RADAI score was 4.59 (2.16), patient global assessment of pain was 52.11 (24.88) on a 100-point scale, and number of painful joints were 7.93 (4.22). RADAI items had good internal consistency with Cronbach's alpha of 0.89 and all item-total correlations >= 0.56. Factor analysis confi rmed one factor with factor loadings of all the items on the factor of >= 0.57. As expected, RADAI scores were signifi cantly correlated with patient global assessment of pain (0.646; P < 0.0001)
